Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Prana Biotechnology Limited ($PRAN) reported that its article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. The company stock soared on the news. The company also said that the article includes pre-clinical data that shows its PBT434 drug candidate lowers levels of alpha-synuclein. Prana also said that PBT434 was shown to prevent loss of nerve cells in the region of the brain primarily affected in Parkinson’s disease.
The company stock showed positive reaction to the announcement. The stock price has gained over 82 percent this year so far.

Alexion Pharmaceuticals ($ALXN) stock soared as the company announced inking a new national funding deal. The company has signed the agreement with the National Institute for Health and Care Excellence and the National Health Service England on Strensiq for patients in England with pediatric-onset hypophosphatasia. Alexion is now working on local funding processes for Strensiq in additional countries worldwide.
The company stock gained over 3 percent in its previous trading session, taking its 12 months gain to 5 percent. The stock has also increased 2 percent on Year to Date basis. Alexion s a biopharmaceutical company and focuses on the development and commercialization of therapeutic products.


Merck ($MRK) announced that the FDA has placed clinical holds on three Keytruda combo therapy trials. The action has been taken due to patient deaths. The FDA decided that the currently available data shows treatment risks outweighing potential benefits for multiple myeloma patients. It had earlier paused new patient enrollment on June 12.
Prothena Corporation ($PRTA) announced initiating a Phase 2 study of PRX002 / RG7935 in early stage Parkinson’s disease. Primary endpoint is to measure the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale total score for each treatment arm.

Edward Lifesciences ($EW) announced receiving the FDA approval for its Inspiris Resilia aortic valve product. The company plans to launch the valve in the US market in early 2018. The product is already commercially available in Europe since earlier this year.
Tonix Pharmaceuticals ($TNXP) announced that the FDA has given its conditional acceptance for proposed trade name Tonmya for TNX-102 SL* (cyclobenzaprine HCl sublingual tablets) for the management of posttraumatic stress disorder (PTSD). A request for review of Tonmya as the proposed name for TNX-102 SL for the management of fibromyalgia has been withdrawn at the FDA.


Vivus ($VVUS) announced that it has settled its patent infringement issue with Actavis Laboratories. The issue pertained to a generic version of weight-loss drug Qsymia. Under the settlement Actavis receives the permission to sell the generic version at the end of 2024, or earlier under certain triggering events.
Cross Country Healthcare ($CCRN) announced closing its acquisition of Advantage RN. The company has taken over substantially all of Advantage's assets for $88 milion, subject to a net working capital adjustment. It paid $19.9 million with cash on hand and $66.9 million through borrowings.

Brokerage Action Company Rating
HC Wainwright Reiterates Second Sight Medical Products (EYES)
Royal Bank Of Canada Upgrades ImmunoGen (IMGN)
Sector Perform -> Outperform
William Blair Reiterates Medtronic PLC (MDT)
Piper Jaffray Companies Reiterates Nuvectra Corporation (NVTR)
Dawson James Reiterates OncoSec Medical Incorporated (ONCS)
Stifel Nicolaus Downgrades Patterson Companies (PDCO)
Hold -> Sell
HSBC Holdings plc Upgrades Shire PLC (SHPG)
Reduce -> Hold
Cowen and Company Reiterates Vertex Pharmaceuticals Incorporated (VRTX)
Market Perform

Gainers (% price change)Last TradeChangeMkt CapAchillion PharmaceuticalsACHN5.15+0.43 (9.11%)724.07MImmunoGen, Inc.IMGN7.30+0.49 (7.20%)624.72MCytokinetics, Inc.CYTK13.05+0.65 (5.24%)650.99MAlnylam PharmaceuticalsALNY85.71+4.01 (4.91%)8.03BConcord Medical ServicesCCM3.89+0.18 (4.85%)169.56MLosers (% price change)Fluidigm CorporationFLDM3.77-0.35 (-8.50%)113.09MCerus CorporationCERS2.32-0.20 (-7.94%)244.24MChina Biologic ProductsCBPO104.97-6.92 (-6.18%)2.82BSTAAR Surgical CompanySTAA10.15-0.40 (-3.79%)405.85MHealthStream, Inc.HSTM25.45-0.94 (-3.56%)813.56MMost Actives (dollar volume)Johnson & JohnsonJNJ133.64+0.74 (0.56%)361.66BPfizer Inc.PFE33.64-0.18 (-0.53%)201.70BGilead Sciences, Inc.GILD70.86+0.16 (0.23%)92.49BUnitedHealth Group IncUNH188.25+1.60 (0.86%)182.61BAmgen, Inc.AMGN174.26+1.46 (0.84%)128.57B